The Japanese market for cancer-related drugs including anticancer agents, colony-stimulating factors, antiemetics and pain relievers will increase 63.4% to 1,069.4 billion yen ($11.01 billion) by 2017 from 654.5 billion yen in 2008, according to a recent survey conducted by Fuji Keizai, a Tokyo-based market research company.
The survey also covers the areas of nutritious preparations, immunosuppressants and anesthetics/muscle relaxants, and reviews the current situation and prospects in the field.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze